Research record
NRAS-mutant melanoma
An NRAS result is a reason to ask mutation-specific treatment and trial questions, especially when BRAF V600 targeted therapy is not the relevant pathway.
What this is
An NRAS result is a reason to ask mutation-specific treatment and trial questions, especially when BRAF V600 targeted therapy is not the relevant pathway.
Why it may come up
- Immunotherapy remains a major melanoma treatment category.
- MEK-inhibitor strategies may come up, but approval and usefulness depend strongly on the specific drug and country.
What not to assume
- Do not describe NRAS as automatically faster for every patient without a source for the exact clinical context.
- Do not imply all MEK inhibitors are approved for NRAS melanoma in all countries.
- Gene
- NRAS
- Cancer type
- melanoma
- Last checked
- 2026-05-20
What we know
- Immunotherapy remains a major melanoma treatment category.
- MEK-inhibitor strategies may come up, but approval and usefulness depend strongly on the specific drug and country.
- Clinical trials may be especially important after PD-1/PD-L1 failure.
What is unclear
- Do not describe NRAS as automatically faster for every patient without a source for the exact clinical context.
- Do not imply all MEK inhibitors are approved for NRAS melanoma in all countries.
Questions to ask
- Which parts of this result are actionable?
- Which parts are mainly useful for trial search?
- Would a melanoma specialty center review change the conversation?